StockNews.AI
ARVN
StockNews.AI
106 days

Kirby McInerney LLP Announces Investigation of Potential Claims Against Arvinas, Inc. (ARVN) on Behalf of Investors

1. Kirby McInerney LLP is investigating potential claims against Arvinas. 2. Arvinas and Pfizer have discontinued vepdegestrant development for breast cancer. 3. The abrupt announcement led to a 25% decline in ARVN's stock price. 4. Investors were caught off guard by the termination of Phase 3 studies. 5. Oppenheimer & Co. questions management transparency regarding clinical progress.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The discontinuation of a key drug development significantly affects investor confidence and company valuation.

How important is it?

The discontinuation of a major drug and potential legal investigation are critical for stock performance.

Why Short Term?

The immediate stock price drop indicates negative sentiment may persist in the near term, but trends could stabilize over time.

Related Companies

PFEAMGNBSX
NEW YORK , May 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ:ARVN). The investigation concerns whether Arvinas and/or certain of its officers have violated the federal securities laws. [LEARN MORE ABOUT THE INVESTIGATION] On May 1, 2025, Arvinas and its partner Pfizer announced that they would discontinue development of vepdegestrant, an oral SERD for HR-positive breast cancer. The move eliminated two planned Phase 3 studies, following the termination of VERITAC-3 in January. According to The Fly, a financial news platform, Oppenheimer & Co. “was surprised by the announcement” and questioned whether “Arvinas’ management isn’t telling us the whole story.” Arvinas had repeatedly pointed to clinical progress for vepdegestrant and the drug’s commercial opportunity, leaving investors caught off guard by the abrupt pivot. On this news, the price of Arvinas shares declined by $2.39 per share, or approximately 25%, from $9.62 per share on April 30, 2025, to close at $7.23 on May 1, 2025. If you purchased or otherwise acquired Arvinas securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out the form below to discuss your rights or interests with respect to these matters without any cost to you. [CONTACT US] Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. ContactsKirby McInerney LLPThomas W. Elrod, Esq.212-699-1180https://www.kmllp.cominvestigations@kmllp.com

Related News